# A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

> **NCT02425826** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 221 (actual)

## Conditions studied

- Parapsoriasis

## Interventions

- **DRUG:** Apremilast
- **DRUG:** Placebo
- **DRUG:** Placebo-Apremilast

## Key facts

- **NCT ID:** NCT02425826
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-20
- **Primary completion:** 2016-02-12
- **Final completion:** 2016-11-22
- **Target enrollment:** 221 (ACTUAL)
- **Last updated:** 2023-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02425826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02425826, "A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02425826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*